Ads
related to: drugs approved for cll- Dosing Information
View Recommended Dosing Schedules
For This Treatment Option.
- Clinical Trial Results
Find Info On Clinical Trials
For This Treatment Option.
- Take The Quiz
Find Out If This Treatment Option
Is Right For You
- Care Partner Support
Find Out More About
Lymphoma Treatment Options
- Dosing Information
Search results
Results from the WOW.Com Content Network
In January 2023, the US Food and Drug Administration (FDA) approved zanubrutinib for chronic lymphocytic leukemia or small lymphocytic lymphoma. [19] In March 2024, FDA granted accelerated approval to zanubrutinib, in combination with obinutuzumab, for relapsed or refractory follicular lymphoma after two or more lines of systemic therapy. [20]
Acalabrutinib, sold under the brand name Calquence, is a medication used to treat various types of non-Hodgkin lymphoma, including mantle cell lymphoma (MCL) and chronic lymphocytic leukemia /small lymphocytic Lymphoma (CLL/SLL). [7] It may be used both in relapsed as well as in treatment-naive settings. [8]
904,000 (2015) [6] Deaths. 60,700 (2015) [7] Chronic lymphocytic leukemia (CLL) is a type of cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell). [2][8] Early on, there are typically no symptoms. [2] Later, non-painful lymph node swelling, feeling tired, fever, night sweats, or weight loss for no clear reason ...
The company said the health regulator gave the new approval to the drug for the treatment of chronic lymphocytic leukemia (CLL), a type of cancer in which the bone marrow makes too many of certain ...
It was approved by the US Food and Drug Administration (FDA) in November 2013, for the treatment of mantle cell lymphoma. [10] In February 2014, the FDA expanded the approved use of ibrutinib to chronic lymphocytic leukemia (CLL). [25] [26] It was approved for Waldenström's macroglobulinemia in 2015. [11] [27]
Alemtuzumab. Alemtuzumab, sold under the brand names Campath and Lemtrada among others, is a medication used to treat chronic lymphocytic leukemia and multiple sclerosis. [8] In chronic lymphocytic leukemia, it has been used as both a first line and second line treatment. [8] It is given by injection into a vein.
Ads
related to: drugs approved for cll